03/14/2026
The FDA is reducing the number of expert advisory committee meetings it holds, even as more controversial or high‑impact decisions go forward without that outside expert input. The move has sparked discussion about transparency, public trust, and how medical and scientific expertise should inform regulatory decisions. Here's more on this.
https://www.statnews.com/2026/03/09/fda-cuts-back-advisory-meetings-controversial-decisions-grow/